^
Association details:
Biomarker:ALK rearrangement
Cancer:Lung Adenocarcinoma
Drug Class:Tyrosine kinase inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P38.05 - Clinical, Genetic, Radiological, and Pathological Characteristics of Cribriform Adenocarcinoma of the Lung

Published date:
01/12/2021
Excerpt:
Twenty-five patients (2.4%) had Cribri-ADC….Among the 10 patients who had tumor recurrences, 8 had EGFR mutations or ALK rearrangement, 6 of whom achieved relatively long survival (median, 64.6 months; range, 37.4–113 months) following treatment with tyrosine kinase inhibitors (TKIs).